ES2811764T3 - Adhesión antileucocitaria para mitigación de posibles eventos adversos causados por dominios de unión específicos de CD3 - Google Patents
Adhesión antileucocitaria para mitigación de posibles eventos adversos causados por dominios de unión específicos de CD3 Download PDFInfo
- Publication number
- ES2811764T3 ES2811764T3 ES14707953T ES14707953T ES2811764T3 ES 2811764 T3 ES2811764 T3 ES 2811764T3 ES 14707953 T ES14707953 T ES 14707953T ES 14707953 T ES14707953 T ES 14707953T ES 2811764 T3 ES2811764 T3 ES 2811764T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- cell
- binding
- adhesion molecule
- endothelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762718P | 2013-02-08 | 2013-02-08 | |
| US201361811526P | 2013-04-12 | 2013-04-12 | |
| PCT/EP2014/052406 WO2014122251A2 (en) | 2013-02-08 | 2014-02-07 | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2811764T3 true ES2811764T3 (es) | 2021-03-15 |
Family
ID=50231117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14707953T Active ES2811764T3 (es) | 2013-02-08 | 2014-02-07 | Adhesión antileucocitaria para mitigación de posibles eventos adversos causados por dominios de unión específicos de CD3 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9688760B2 (enExample) |
| EP (2) | EP2953630B1 (enExample) |
| JP (2) | JP6567425B2 (enExample) |
| AR (1) | AR094740A1 (enExample) |
| AU (2) | AU2014214020B2 (enExample) |
| CA (1) | CA2898032C (enExample) |
| ES (1) | ES2811764T3 (enExample) |
| JO (1) | JO3529B1 (enExample) |
| MX (2) | MX368842B (enExample) |
| TW (2) | TWI704920B (enExample) |
| UY (1) | UY35313A (enExample) |
| WO (1) | WO2014122251A2 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2701741B1 (en) * | 2011-04-28 | 2020-06-10 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2014056783A1 (en) | 2012-10-08 | 2014-04-17 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| US9486475B2 (en) * | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| JP6499087B2 (ja) | 2013-02-26 | 2019-04-10 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| WO2014131712A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US10101247B2 (en) * | 2013-07-19 | 2018-10-16 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
| MX379030B (es) | 2013-12-17 | 2025-03-10 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
| FI3531133T3 (fi) | 2014-05-30 | 2023-11-02 | Amgen Res Munich Gmbh | Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu |
| RS65573B1 (sr) | 2014-08-04 | 2024-06-28 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| BR112017010513A2 (pt) | 2014-11-20 | 2018-04-03 | F. Hoffmann-La Roche Ag | ?cadeias leves comuns e métodos de uso? |
| FI4141032T3 (fi) | 2014-11-20 | 2024-07-31 | Hoffmann La Roche | T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito |
| EP3221356B1 (en) | 2014-11-20 | 2020-09-02 | F.Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules against folr1 and cd3 |
| HRP20231134T1 (hr) | 2015-06-16 | 2024-01-05 | F. Hoffmann - La Roche Ag | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu |
| CN107847568B (zh) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | 抗cll-1抗体和使用方法 |
| WO2017040324A1 (en) * | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CN106554414B (zh) * | 2015-09-18 | 2019-04-23 | 上海科济制药有限公司 | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| KR20180073561A (ko) | 2015-10-02 | 2018-07-02 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자 |
| US10101248B1 (en) * | 2015-12-02 | 2018-10-16 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
| AU2016368469B2 (en) | 2015-12-09 | 2023-11-02 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody for reducing formation of anti-drug antibodies |
| AR107303A1 (es) | 2016-01-08 | 2018-04-18 | Hoffmann La Roche | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit |
| LT3433280T (lt) | 2016-03-22 | 2023-07-10 | F. Hoffmann-La Roche Ag | Proteazės aktyvuojamos t ląstelei bispecifinės molekulės |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| JP6225321B1 (ja) * | 2016-08-31 | 2017-11-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
| EP3677587A4 (en) | 2016-08-31 | 2021-04-14 | Oji Holdings Corporation | XYLOOLIGOSACCHARIDE ACID, AND METHOD FOR MANUFACTURING THE SAME |
| US10882918B2 (en) | 2016-09-30 | 2021-01-05 | Hoffmann-La Roche Inc. | Bispecific T cell activating antigen binding molecules |
| KR20190074300A (ko) | 2016-11-15 | 2019-06-27 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| JP6281659B1 (ja) | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CA3065747C (en) | 2017-05-31 | 2024-10-01 | Oji Holdings Corporation | MOISTURIZING COMPOSITION CONTAINING PENTOSANNE POLYSULFATE |
| AU2018333249B2 (en) | 2017-09-12 | 2023-03-02 | Oji Holdings Corporation | Pentosan polysulfate and method for producing pentosan polysulfate |
| CN111148533A (zh) | 2017-09-19 | 2020-05-12 | 麻省理工学院 | 用于嵌合抗原受体t细胞疗法的组合物及其用途 |
| WO2019124363A1 (ja) | 2017-12-20 | 2019-06-27 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン及びポリ硫酸ペントサンを含む医薬 |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| WO2019156795A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| EP3962948A1 (en) * | 2019-04-30 | 2022-03-09 | Amgen Research (Munich) GmbH | Means and methods of treating burkitt lymphoma or leukemia |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| BR112022011357A2 (pt) | 2019-12-13 | 2022-08-23 | Genentech Inc | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo |
| KR20220163940A (ko) | 2020-02-04 | 2022-12-12 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 항-디니트로페놀 키메라 항원 수용체 |
| US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
| CA3173527A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
| CA3171235A1 (en) * | 2020-03-12 | 2021-09-16 | Sydney David Cullis-Hill | Treatment for coronavirus infection and associated cytokine toxicity |
| WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
| WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| TWI852680B (zh) | 2020-06-19 | 2024-08-11 | 瑞士商赫孚孟拉羅股份公司 | 與 cd3 及 cd19 結合之抗體 |
| WO2022060901A1 (en) * | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| AU2021374590A1 (en) | 2020-11-04 | 2023-06-01 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
| KR20230095113A (ko) | 2020-11-04 | 2023-06-28 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약 |
| CN112521513B (zh) * | 2020-12-15 | 2021-08-24 | 青岛西凯生物技术有限公司 | 一种靶向cd19的嵌合抗原受体(car)及其应用 |
| WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN113637087A (zh) * | 2021-07-09 | 2021-11-12 | 上海易慕峰生物科技有限公司 | 一种提高细胞免疫疗法安全性的嵌合受体和细胞 |
| US20260083848A1 (en) | 2021-11-03 | 2026-03-26 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2024206166A1 (en) * | 2023-03-31 | 2024-10-03 | Memorial Sloan-Kettering Cancer Center | Microenvironment actuated t-cells and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2689848A (en) | 1951-02-06 | 1954-09-21 | Wander Ag Dr A | Salts of sulfuric acid esters of xylan |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| AU687755B2 (en) * | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| SI1976886T1 (sl) | 2005-12-16 | 2015-03-31 | Amgen Research (Munich) Gmbh | Sredstva in postopki za zdravljenje tumorskih bolezni |
| AU2007248019B2 (en) | 2006-05-03 | 2012-10-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric T cell receptors and related materials and methods of use |
| MX2008015771A (es) * | 2006-06-14 | 2009-01-27 | Macrogenics Inc | Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida. |
| WO2008107906A1 (en) | 2007-03-06 | 2008-09-12 | Alembic Limited | Process for the preparation of pentosan polysulfate or salts thereof |
| SG10201808730VA (en) * | 2007-04-03 | 2018-11-29 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发（慕尼黑）股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
| US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
| EA201000219A1 (ru) * | 2007-07-17 | 2010-12-30 | Комбинейторкс, Инкорпорейтед | Способ и композиция для лечения в-клеточных пролиферативных нарушений |
| WO2009011897A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Combinations for the treatment of b-cell proliferative disorders |
| EP2188281A1 (en) | 2007-08-10 | 2010-05-26 | Y's Therapeutics Co, Ltd. | Modulation of immune responses by administration of roxithromycin or its derivative |
| US8026343B2 (en) * | 2008-08-08 | 2011-09-27 | Dinona Inc. | Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof |
| EP4180458A1 (en) * | 2008-10-01 | 2023-05-17 | Amgen Research (Munich) GmbH | Cross-species-specific psma x cd3 bispecific single chain antibody |
| BR112012009778A2 (pt) * | 2009-10-27 | 2017-06-13 | Micromet Ag | regime de dosagem para administrar um anticorpo biespecífico de cd19xcd3 |
| KR101889995B1 (ko) * | 2010-10-27 | 2018-08-20 | 암젠 리서치 (뮌헨) 게엠베하 | Dlbcl의 치료 수단 및 방법 |
| SMT201700250T1 (it) * | 2010-11-10 | 2017-07-18 | Amgen Res Munich Gmbh | Prevenzione di effetti avversi provocati da domini leganti cd3 specifici |
| US9402865B2 (en) * | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| EP2701741B1 (en) * | 2011-04-28 | 2020-06-10 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CN102875685B (zh) | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
| US9486475B2 (en) * | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
-
2014
- 2014-02-06 JO JOP/2014/0028A patent/JO3529B1/ar active
- 2014-02-07 EP EP14707953.7A patent/EP2953630B1/en active Active
- 2014-02-07 MX MX2015009922A patent/MX368842B/es active IP Right Grant
- 2014-02-07 UY UY0001035313A patent/UY35313A/es unknown
- 2014-02-07 JP JP2015556506A patent/JP6567425B2/ja active Active
- 2014-02-07 CA CA2898032A patent/CA2898032C/en active Active
- 2014-02-07 EP EP20182831.6A patent/EP3760210A1/en not_active Withdrawn
- 2014-02-07 AR ARP140100416A patent/AR094740A1/es unknown
- 2014-02-07 ES ES14707953T patent/ES2811764T3/es active Active
- 2014-02-07 WO PCT/EP2014/052406 patent/WO2014122251A2/en not_active Ceased
- 2014-02-07 TW TW103104162A patent/TWI704920B/zh active
- 2014-02-07 MX MX2019012421A patent/MX2019012421A/es unknown
- 2014-02-07 TW TW107140068A patent/TW201929865A/zh unknown
- 2014-02-07 AU AU2014214020A patent/AU2014214020B2/en active Active
- 2014-02-08 US US14/176,091 patent/US9688760B2/en active Active
-
2017
- 2017-05-24 US US15/604,341 patent/US11084876B2/en active Active
-
2019
- 2019-02-07 AU AU2019200841A patent/AU2019200841B2/en active Active
- 2019-05-28 JP JP2019098999A patent/JP6933684B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2898032C (en) | 2021-06-15 |
| JP6567425B2 (ja) | 2019-08-28 |
| US20140227272A1 (en) | 2014-08-14 |
| MX368842B (es) | 2019-10-18 |
| MX2019012421A (es) | 2022-10-13 |
| JP2016514090A (ja) | 2016-05-19 |
| UY35313A (es) | 2014-08-29 |
| WO2014122251A3 (en) | 2014-10-02 |
| CA2898032A1 (en) | 2014-08-14 |
| EP2953630B1 (en) | 2020-07-01 |
| TW201929865A (zh) | 2019-08-01 |
| AU2014214020B2 (en) | 2018-11-15 |
| WO2014122251A2 (en) | 2014-08-14 |
| AU2019200841B2 (en) | 2020-08-13 |
| EP2953630A2 (en) | 2015-12-16 |
| AU2014214020A1 (en) | 2015-07-30 |
| HK1216996A1 (zh) | 2016-12-16 |
| TWI704920B (zh) | 2020-09-21 |
| US9688760B2 (en) | 2017-06-27 |
| JP6933684B2 (ja) | 2021-09-08 |
| MX2015009922A (es) | 2015-09-25 |
| TW201442714A (zh) | 2014-11-16 |
| JP2019178142A (ja) | 2019-10-17 |
| EP3760210A1 (en) | 2021-01-06 |
| AU2019200841A1 (en) | 2019-02-28 |
| US20170327581A1 (en) | 2017-11-16 |
| AR094740A1 (es) | 2015-08-26 |
| US11084876B2 (en) | 2021-08-10 |
| JO3529B1 (ar) | 2020-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6933684B2 (ja) | Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着 | |
| ES2981569T3 (es) | Métodos de tratamiento usando terapia celular adoptiva | |
| JP7523084B2 (ja) | 抗ガレクチン－９抗体及びその使用 | |
| US12227575B2 (en) | Combination of TIM-4 antagonist and PD-1 antagonist and methods of use | |
| JP2019517773A (ja) | 抗ｌａｇ−３抗体 | |
| JP2019513400A (ja) | エクスビボのｂｉｔｅ活性化ｔ細胞 | |
| US20230125234A1 (en) | Anti cd44-ctla4 bispecific antibodies | |
| CN111655286A (zh) | 作为免疫调节剂的cd96结合剂 | |
| Markmann et al. | On the road to eliminating long‐lived plasma cells—“are we there yet?” | |
| Bakacs et al. | Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy) | |
| CA3233512A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers | |
| CA2948771C (en) | Risk-stratification of b-precursor acute lymphoblastic leukemia patients | |
| US20240294623A1 (en) | Tgf-beta inhibitors and therapeutic use thereof | |
| ES2975410T3 (es) | Anticuerpos biespecíficos que se unen a HVEM y CD9 | |
| CN118742323A (zh) | Kir3dl3抑制剂和免疫细胞激活剂 | |
| KR20260026100A (ko) | 항-카텝신-d 항체 | |
| Keats et al. | Daratumumab induces CD38 internalization and impairs myeloma cell adhesion |